MaxCyte Inc’s (LON:MXCT) Flow Electroporation technology will be used by CRISPR Therapeutics as part of its quest to develop new gene therapies for the treatment of cancer after the pair signed a commercial licence agreement.
Doug Doerfler, MaxCyte chief executive, said the agreement was a “validation” of his firm’s technology, while CRISPR boss, Samarth Kulkarni, said he was pleased to have secured access to “the leading ex vivo delivery platform for both clinical and commercial use”.
Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.
In this case, CRISPR will use the technology to deliver its components into T-cells which attack the body’s own cells that have been invaded by viruses or bacteria.
Today’s (Friday’s) tie-up expands the relationship between MaxCyte and CRISPR. The two signed a deal last year which allowed the latter to use Flow Electroporation as part of its efforts to develop treatments for haemoglobin-related diseases.
In return for supplying its technology, MaxCyte will receive milestone and sales-based payments in addition to other licensing fees.
“The expansion of our relationship with CRISPR Therapeutics signifies a key milestone for MaxCyte and our technology, providing further validation for the value and versatility of our technology as a leading enabler of next-generation cell-based therapies," said MaxCyte President and CEO Doug Doerfler.
“CRISPR Therapeutics is a leader in gene editing, and we are very pleased to expand our collaboration into new therapeutic areas as we continue to explore the use of our technology to advance medicines to market that will make a difference for patients.”